The global helicobacter pylori infections treatment market is expected to surpass an impressive valuation of US$ 638.3 Million in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 7.04% from 2023 to 2033, reaching US$ 1,260 Million.
Helicobacter pylori (H. pylori) is a gram-negative aerobic bacterium that is frequently found in the stomach. While it helps to maintain the stomach ecology, it can also induce infections of the stomach lining. The bacteria can be one of the causes of stomach cancer, peptic ulcers, gastritis, small intestine contagion, and peptic ulcer disease. This has heightened the need for H. pylori infection diagnostic techniques.
The dispersion of such infections can be linked to a variety of aspects, along with a lack of adequate water supply, poor sanitation, a high population, and poor personal hygiene. Increased awareness of H. pylori infections in the cohort is one of the variables affecting the Helicobacter pylori diagnostics market's expansion. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 638.3 Million |
| Anticipated Forecast Value (2033) | US$ 1,260 Million |
| Projected Growth Rate (2023 to 2033) | 7.04% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
COVID-19 is an unprecedented global public health crisis that has impacted nearly every marketplace, and the lengthy effects are expected to have an influence on the industry's expansion over the forecast period. Our continuing research expands our research framework to include underlying COVID-19 concerns and potential next steps.
Antibiotic availability and affordability in addition to shorter processing duration will increase antibiotic implementation and requirement for pre and post-surveillance tests. Moreover, rising H. pylori infection rates, the necessity for early diagnosis of symptoms, and technological innovations in diagnostic procedures are estimated to drive overall growth over the forecast period.
Soaring Infectious Disease Incidence Rates and Increased Awareness to propel growth
The growing incidence of communicable diseases and soaring public awareness about infections are the key causes of the industry. Tuberculosis, Chlamydia, gonorrhea, other sexually transmitted illnesses (STDs), stomach flu (gastroenteritis), and bladder infections represent the most prevalent infectious illnesses caused by viruses (UTIs).
For example, according to a research released in 2021 titled "The Global Prevalence of Peptic Ulcer in the World: A Systematic Review and Meta-analysis," the worldwide incidence of peptic ulcer was around 8.4% in 2021. Because helicobacter pylori diagnostics are widely accepted for infectious disease diagnosis, such occurrences indicate that the market is projected to expand at a substantial rate over the coming years.
Diagnostic cost-effectiveness and the necessity for personalized antibiotic therapy drive market expansion
The market is expanding due to increased diagnostic cost-effectiveness and the requirement for personalized antibiotic therapy. The accessibility of low-cost antibiotics and short processing durations are anticipated to boost antibiotic regimen implementation, which will benefit consumers for both pre-and post-monitoring tests.
Furthermore, a rise in the prevalence of Helicobacter pylori infection, higher demand for early recognition of symptoms, and advancements in diagnostic methods all contribute to the market's growth.
Principal Consultant
Diagnostic test restrictions limit growth in the economy
Diagnostic test constraints are predicted to be a significant impediment to the expansion of the Helicobacter pylori diagnostics market. Serology-based assays, for example, have low sensitivity and specificity because they cannot distinguish between acute illness and IgG antibodies present after treatment.
North American Market Growth is credited to rising transmissible diseases
Over the projected timeframe, North America is likely to dominate the global helicobacter pylori diagnostics industry. The rise is attributed to aspects such as a rise in the instances of transmissible diseases, increased awareness of infectious diseases, and the introduction of new products.
For example, Biomerica Inc. announced in June 2021 that it had signed an exclusive five-year partnership deal with a Canadian partner for the marketing and sale of Biomerica's new and proprietary Helicobacter pylori test, hp+detect. The hp+detect product was created to identify and supervise helicobacter pylori infection, which is the major cause of stomach and duodenal ulcers and a health risk for gastric cancer.
As a result, such occurrences are expected to propel market expansion in the region. The gender representation of H. pylori infection indicates a male predominance worldwide, with an estimated 62,500,000 male and approximately 56,900,000 female cases in the United States in 2021.
Europe is estimated to have the second-highest volume of H. pylori sales
Europe is expected to possess the second-largest H. pylori sales volume, with 30% revenue by 2022. The extensive use of antibiotics in several countries is an important factor. Furthermore, rising investments and the emergence of different major influencers are being assessed as potential drivers of market growth.
The European Helicobacter Pylori Infections Treatment market is forecast to be the second biggest. The growing number of patients seeking an early diagnosis of helicobacter pylori infection in order to avoid peptic ulcers is predicted to boost the market growth in the European region.
Based on the National Institute for Health Research, Helicobacter pylori is prevalent in most nations, along with North European communities, in which an estimated one-third of grownups are still contaminated, meanwhile, the incidence is higher than 50% in South America, Asia, and south and east Europe. Moreover, Helicobacter pylori are still prominent in immigrants from Helicobacter pylori-endemic European countries. These aspects are predicted to propel the global helicobacter pylori testing market in Europe forward.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The diagnostic laboratories segment to grow at the fastest pace
During the forecast period, the diagnostic laboratories segment is anticipated to expand at the fastest rate. The primary reasons for healthy growth are more specialized and effective infection identification, along with greater awareness of infectious diseases.
In regards to revenue, the hospitals and diagnostics laboratories segments were responsible for more than 82% of the industry in 2022.
HDDT (high-dose dual therapy) segment to Grow Rapidly
Bismuth quadruple therapy (BQT) is currently widely used to eliminate H pylori. High-dose dual therapy (HDDT) is an effective alternative diagnosis.
As per the latest analysis, both BQT and HDDT can achieve comparable elimination rates and adherence, with HDDT causing fewer side effects in general. As a result, these segments are expected to witness major market growth.
The growing number of start-ups in the Helicobacter Pylori Infections Treatment market has increased product quality and worldwide sales. Furthermore, in order to gain a competitive edge, new start-ups are operating on recent developments and releasing new products such as:
Key players in the helicobacter pylori infections treatment market are Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM-H. pylori.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 638.3 Million |
| Market Value in 2033 | US$ 1,260 Million |
| Growth Rate | CAGR of 7.04% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, Application, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Phathom Pharmaceuticals; Redhill Biopharma; Takeda Pharmaceuticals; AbbVie; Cumberland Pharmaceuticals; Eisai Co.; Bio-Rad Laboratories; F. Hoffmann-La Roche; Alpha Laboratories; Biohit |
| Customization | Available Upon Request |
FMI projects the global Helicobacter Pylori Infections Treatment market to expand at a 7.04% value CAGR by 2033.
The global Helicobacter Pylori Infections Treatment market is estimated at a market value of US$ 638.3 Million.
The global Helicobacter Pylori Infections Treatment market is expected to garner a market value of US$ 1,260 Million.
FMI has projected North America to be one of the key regions for the Helicobacter Pylori Infections Treatment market.
Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM-H.pylori.
1. Executive Summary | Helicobacter Pylori Infections Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Bismuth-quadruple Therapy
5.3.2. Concomitant Therapy
5.3.3. Levofloxacin Triple Therapy
5.3.4. Bismuth Therapy
5.3.5. High-dose Dual Therapy
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Hospitals
6.3.2. Diagnostics Laboratories
6.3.3. Clinics
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The US
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Application
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. The UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Application
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Application
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Application
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. The US.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By Application
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By Application
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By Application
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By Application
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By Application
13.6. The UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By Application
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By Application
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By Application
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By Application
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By Application
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By Application
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By Application
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By Application
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By Application
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By Application
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By Application
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By Application
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By Application
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By Application
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By Application
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By Application
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Phathom Pharmaceuticals
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Redhill Biopharma
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Takeda Pharmaceutical
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. AbbVie
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Cumberland Pharmaceuticals
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Eisai Co
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Bio-Rad Laboratories
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. F. Hoffmann-La Roche
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Alpha Laboratories
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Biohit
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Helicobacter Pylori Infections Treatment Market
